Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients
Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients
复制标题
DOI：
10.1111/eci.13201
复制
发表时间：
2020-02-12
影响因子：
5.5
通讯作者：
Portincasa, Piero
中科院分区：
文献类型：
--
作者：
Bonfrate, Leonilde;Di Palo, Domenica M.;Portincasa, Piero
背景肠易激综合征（IBS）是一种常见的胃肠道疾病，目前仍缺乏有效的治疗方法。我们的目的是研究长双歧杆菌 BB536 和鼠李糖乳杆菌 HN001 与维生素 B6 (LBB) 的新型制剂对 IBS 受试者的症状、肠道通透性、可培养细菌和代谢组的影响。 材料和方法 25 名 IBS 患者（罗马 IV 标准）（M:F = 8:17；年龄 48 岁 +/- 11 SD）被随机接受治疗 (LBB)或安慰剂（各一个月）在交叉随机双盲对照试验中。在第 0 天、30 天、45 天和 60 天时分析症状、肠道习惯、疾病严重程度、肠道通透性和肠道微生物群。结果 与基线相比，LBB 组腹痛（-48.8% vs -3.5%）、腹胀（-36.35% vs +7.35%）和疾病严重程度（-30.1% vs -0.4%）的百分比显着（P < .0001）更大。分别为安慰剂。在 IBS-D 患者中，Bristol 评分较基线的改善与 LBB 更为一致（从 6 +/- 0.4 到 4.3 +/- 1.1，P < .00001），而不是安慰剂（从 6.2 +/- 0.7 到 5.3 +/- 1.1，P = .04）。在 IBS-C 患者中，LBB 后布里斯托尔评分往往较基线有所改善（2.6 +/- 1.1 vs 3.2 +/- 0.5，P = .06）。 LBB 显着提高了三氯蔗糖恢复百分比（结肠渗透性）（1.86 +/- 0.1 vs 1.1 +/- 0.2，P = .01）。在治疗过程中，假定的乳酸菌和双歧杆菌、丙酸、丁酸、戊酸和碳氢化合物的相对丰度增加，而苯酚减少。 结论 含有 B6 维生素的长双歧杆菌 BB536 和鼠李糖乳杆菌 HN001 的新配方可改善 IBS 患者的症状和疾病严重程度，恢复肠道通透性和肠道微生物群。
Background Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, which still lacks effective therapy. We aimed to investigate the effects of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6 (LBB) on symptoms, intestinal permeability, cultivable bacteria and metabolome in IBS subjects.Materials and methods Twenty-five IBS patients (Rome IV criteria) (M:F = 8:17; age 48 years +/- 11 SD) were randomized to treatment (LBB) or placebo (one month each) in a crossover randomized double-blind controlled trial. Symptoms, intestinal habits, disease severity, intestinal permeability and intestinal microbiota were analysed at 0, 30, 45 and 60 days.Results Percentage decrease from baseline of abdominal pain (-48.8% vs -3.5%), bloating (-36.35% vs +7.35%) and severity of disease (-30.1% vs -0.4%) was significantly (P < .0001) greater with LBB than placebo, respectively. In IBS-D patients, the improvement from baseline of Bristol score was more consistent with LBB (from 6 +/- 0.4 to 4.3 +/- 1.1, P < .00001) than placebo (from 6.2 +/- 0.7 to 5.3 +/- 1.1, P = .04). In IBS-C patients, Bristol score tended to improve from baseline after LBB (2.6 +/- 1.1 vs 3.2 +/- 0.5, P = .06). LBB significantly improved the percentage of sucralose recovery (colonic permeability) (1.86 +/- 0.1 vs 1.1 +/- 0.2, P = .01). During treatment, presumptive lactic acid bacteria and bifidobacteria, relative abundance of propanoic, butanoic, pentanoic acids and hydrocarbons increased, while phenol decreased.Conclusions The novel formulation of B. longum BB536 and L. rhamnosus HN001 with B6 vitamin improves symptoms and severity of disease, restores intestinal permeability and gut microbiota in IBS patients.